Panbela Therapeutics (OTCMKTS:PBLA – Get Free Report) is expected to release its resultson Thursday, May 14th. Analysts expect Panbela Therapeutics to post earnings of ($2,640.00) per share for the quarter.
Panbela Therapeutics Price Performance
Shares of PBLA opened at $0.00 on Thursday. The business’s 50 day moving average is $0.01 and its two-hundred day moving average is $0.01. Panbela Therapeutics has a 52-week low of $0.00 and a 52-week high of $0.39.
Panbela Therapeutics Company Profile
Panbela Therapeutics, Inc (NASDAQ: PBLA) is a clinical‐stage biotechnology company focused on developing first‐in‐class therapies that modulate polyamine metabolism to treat aggressive cancers. The company’s lead investigational compound, SBP-101, is a proprietary stabilized spermine analogue designed to induce tumor cell apoptosis by dysregulating polyamine levels. Panbela has centered its pipeline largely on SBP-101 in combination with standard‐of‐care regimens for high‐mortality indications such as metastatic pancreatic adenocarcinoma and high‐risk myelodysplastic syndromes (HR-MDS).
In its pancreatic cancer program, Panbela is evaluating SBP-101 alongside gemcitabine and nab-paclitaxel in a Phase 1b/2 study, with interim data having been presented at major oncology conferences.
Featured Stories
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
